| Literature DB >> 34771016 |
Maryam Baeeri1, Tina Didari1, Madiha Khalid1, Solmaz Mohammadi-Nejad1, Seyed Mojtaba Daghighi1, Ramtin Farhadi1, Mahban Rahimifard1, Zahra Bayrami1, Hamed Haghi-Aminjan2, Roham Foroumadi3, Mahdi Gholami1, Mohammad Abdollahi1,4.
Abstract
Arsenic (As) poisoning is widespread due to exposure to pollution. The toxic level of (As) causes oxidative stress-induced aging and tissue damage. Since melatonin (MLT) has anti-oxidant and anti-aging properties, we aimed to evaluate the protective effect of MLT against the toxicity of sodium arsenite (NaAsO2). Healthy male NMRI mice were divided into eight different groups. The control group received a standard regular diet. Other groups were treated with varying diets, including MLT alone, NaAsO2, and NaAsO2 plus MLT. After one month of treatment, biochemical and pathological tests were performed on blood, heart, and lung tissue samples. NaAsO2 increased the levels of TNF-α, 8-hydroxy-2-deoxy guanosine (8OHdG), malondialdehyde (MDA), reactive oxygen species (ROS), and high mobility group box 1 (HMGB1), increased the expression of TNF receptor type 1-associated death domain (TRADD) mRNA and telomerase reverse transcriptase, and decreased the expression of Klotho (KL) mRNA in both plasma and tissues. In contrast, MLT reduced MDA, ROS, HMGB1, lactate, and TNF-α enhanced the mRNA expression of KL, and suppressed the mRNA expression of the TERT and TRADD genes. Thus, MLT confers potent protection against NaAsO2- induced tissue injury and oxidative stress.Entities:
Keywords: Klotho; Melatonin; TERT; TRADD; aging; sodium arsenite
Mesh:
Substances:
Year: 2021 PMID: 34771016 PMCID: PMC8587717 DOI: 10.3390/molecules26216603
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Total As concentration in heart and lung tissues.
| Heart Tissue | Lung Tissue | ||
|---|---|---|---|
| Groups | Total As Concentration | Total As Concentration | |
| Control | 50 ± 3 | 25 ± 3 | |
| MLT | 48 ± 2 | 23 ± 2 | |
| NaAsO2 | 1/2 | 475 ± 33 *** | 425 ± 23 *** |
| 1/3 | 325 ± 25 *** | 300 ± 23 *** | |
| 1/10 | 200 ± 20 * | 175 ± 18 * | |
| NaAsO2 + MLT | 1/2 | 375 ± 33 | 300 ± 25 |
| 1/3 | 250 ± 15 # | 200 ± 8 # | |
| 1/10 | 175 ± 13 ## | 100 ± 3 ## | |
Abbreviations: MLT; melatonin, NaAsO2; sodium arsenite. *** p < 0.0001; * p < 0.05 (Vs. control) ## p < 0.001; # p < 0.05 (Vs. ½ LD50 NaAsO2).
Assessment of oxidative stress biomarkers.
| Oxidative Stress Biomarker | |||||
|---|---|---|---|---|---|
| Heart Tissue | Lung Tissue | ||||
| Groups | MDA | ROS | MDA | ROS | |
| Control | 0.71 ± 0.05 | 0.72 ± 0.05 | 0.50 ± 0.05 | 0.40 ± 0.05 | |
| MLT | 0.69 ± 0.05 | 0.69 ± 0.04 | 0.57 ± 0.04 | 0.42 ± 0.03 | |
| NaAsO2 | 1/2 | 1.67 ± 0.11 *** | 1.87 ± 0.07 *** | 1.46 ± 0.11 *** | 1.50 ± 0.09 *** |
| 1/3 | 1.46 ± 0.06 *** | 1.68 ± 0.06 *** | 1.43 ± 0.09 *** | 1.36 ± 0.06 *** | |
| 1/10 | 1.14 ± 0.07 * | 1.33 ± 0.03 *** | 0.93 ± 0.07 * | 1.01± 0.03 *** | |
| NaAsO2 + MLT | 1/2 | 1.30 ± 0.07 # | 1.05 ± 0.06 ### | 1.09 ± 0.07 # | 0.65 ± 0.05 ### |
| 1/3 | 0.97 ± 0.09 ### | 0.89 ± 0.05 ### | 0.84 ± 0.06 ### | 0.64 ± 0.08 ### | |
| 1/10 | 0.88 ± 0.06 ### | 0.74 ± 0.04 ### | 0.62 ± 0.06 ### | 0.43 ± 0.04 ### | |
Abbreviations: MDA: malondialdehyde; ROS: reactive oxygen species; MLT; melatonin, NaAsO2; sodium arsenite; Results are expressed as mean ± SEM for five animals in each group (n = 5). The ROS values are presented as (mol/min/mg protein). *** p < 0.0001; * p < 0.05 (Vs. control or melatonin) ### p < 0.0001; # p < 0.05 (Vs. ½ LD50 NaAsO2).
Figure 1Assessment of pro-inflammatory TNF-α. Abbreviations: TNF-α: tumor necrosis factor-alpha; MLT; melatonin, NaAsO2; sodium arsenite; Results are expressed as mean ± SEM for five animals in each group (n = 5). *** p < 0.0001 (Vs. control or melatonin) ### p < 0.0001; # p < 0.05 (Vs. ½ LD50 NaAsO2).
Figure 2Assessment of High Mobility Group Box 1 (A) High Mobility Group Box 1 levels in heart; (B) High Mobility Group Box 1 levels in lung Abbreviations: HMGB1: High Mobility Group Box 1; MLT; melatonin, NaAsO2; sodium arsenite; Results are expressed as mean ± SEM for five animals in each group (n = 5). *** p < 0.0001; * p < 0.05 (Vs. control or melatonin). ### p < 0.0001; ## p < 0.001; # p < 0.05 (Vs. ½ LD50 NaAsO2).
Figure 3Assessment of 8-hydroxy-2-deoxyguanosine Abbreviations: 8OHdG: 8-hydroxy-2-deoxyguanosine; MLT; melatonin, NaAsO2; sodium arsenite; Results are expressed as mean ± SEM for five animals in each group (n = 5). *** p < 0.0001 (Vs. control or melatonin) ### p < 0.0001; # p < 0.05 (Vs. ½ LD50 NaAsO2).
Assessment of lactate.
| Lactate Level | |||
|---|---|---|---|
| Heart Tissue | Lung Tissue | ||
| Groups | Lactate (mmol/mg protein) | Lactate (mmol/mg protein) | |
| Control | 0.73 ± 0.04 | 0.55 ± 0.04 | |
| MLT | 0.71 ± 0.09 | 0.51 ± 0.04 | |
| NaAsO2 | 1/2 | 1.30 ± 0.07 *** | 1.34 ± 0.11 *** |
| 1/3 | 1.25 ± 0.04 *** | 0.95 ± 0.04 * | |
| 1/10 | 1.63 ± 0.06 *** | 0.92 ± 0.05 * | |
| NaAsO2 + MLT | 1/2 | 0.96 ± 0.06 ### | 0.83 ± 0.07 ### |
| 1/3 | 0.93 ± 0.04 ### | 0.71 ± 0.03 ### | |
| 1/10 | 1.07 ± 0.07 ### | 0.65 ± 0.07 ### | |
Lactate levels in heart & lung tissuesAbbreviations: MLT; melatonin, NaAsO2; sodium arsenite; Results are expressed as mean ± SEM for five animals in each group (n = 5). *** p < 0.0001; * p < 0.05 (Vs. control or melatonin) ### p < 0.0001 (Vs. 1/10 LD50 NaAsO2 in heart and Vs. ½ LD50 NaAsO2 in lungs).
Figure 4Quantitative real-time reverse transcription PCR for gene expression (A) Telomerase reverse transcriptase (TERT) gene expression; (B) Type 1 associated death domain tumor necrosis factor receptor (TRADD) gene expression; (C) Klotho related (KL) gene expression. Abbreviations: MLT; melatonin, NaAsO2; sodium arsenite; Results are expressed as mean ± SEM. Samples were analyzed in triplicate. *** p < 0.0001; ** p < 0.001; * p < 0.05 (Vs. control or melatonin) ### p < 0.0001; ## p < 0.001; # p < 0.05 (Vs. ½ LD50 NaAsO2).
Figure 5Hematoxylin–eosin-stained sections of tissues retrieved from animals treated with melatonin and arsenic in 1/2, 1/3, 1/10 doses, obtained at sacrifice after 30 days’ post-treatment. Black arrow refers to myocardial necrosis, Red arrow refers to inflammatory cells, Blue refers to Edema, Green arrow refers to hyperemia.
Histopathological scoring.
| Histopathological Changes | |||||
|---|---|---|---|---|---|
| Groups | Edema | Congestion | Muscle Necrosis | Hemorrhage | |
| Control | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | |
| MLT | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | |
| NaAsO2 | 1/2 | 3.33 ± 0.33 *** | 2.33 ± 0.33 *** | 4.67 ± 0.33 *** | 2.00 ± 0.58 * |
| 1/3 | 0.33 ± 0.58 ### | 0.00 ± 0.00 ### | 0.67 ± 0.33 ### | 0.67 ± 0.33 | |
| 1/10 | 0.00 ± 0.00 ### | 0.00 ± 0.00 ### | 0.00 ± 0.00 ### | 0.00 ± 0.00 # | |
| NaAsO2 + MLT | 1/2 | 2.33 ± 1.52 ** | 1.33 ± 0.33 ***# | 3.00 ± 0.58 ***# | 1.67 ± 0.67 |
| 1/3 | 0 ± 0 ### | 0.00 ± 0.00 ### | 0.33 ± 0.33 ### | 0.33 ± 0.33 | |
| 1/10 | 0 ± 0 ### | 0.00 ± 0.00 ### | 0.00 ± 0.00 ### | 0.00 ± 0.00 # | |
Abbreviations: MLT; melatonin, NaAsO2; sodium arsenite; Results are expressed as mean ± SEM for five animals in each group (n = 5). *** p < 0.0001; ** p < 0.001, * p < 0.05 (Vs. control or melatonin) ### p < 0.0001; # p < 0.05 (Vs. ½ LD50 NaAsO2).
Figure 6Study design.
The primers of genes used for RT-PCR.
| Gene Name Primer | Gene Symbol | Accession No. | Primer Sequence (5′−3′) |
|---|---|---|---|
|
| beta (Actb) | NM_007393.5 | F: CAGCAAGCAGGAGTACGATGA |
|
| TRADD | NM_001033161.2 | F: CGTGATGGGCTATACGAGCA |
|
| KL | NM_013823.2 | F: GTTCTGCACTTCTACCGCTG |
|
| TERT | NM_001362388.1 | F: CTGCAGGACACACCGTCTAT |
Figure 7The role and mechanism of melatonin in alleviating NaAsO2-induced aging. Abbreviations: ROS: reactive oxygen species; LPO: lipid peroxidation; HMGB1: high mobility group box 1; TRADD: Tumour necrosis factor-α (TNF-α) receptor type 1-associated death domain; TERT: telomerase reverse transcriptase; KL: Klotho.